VGF (nonacronymic) is a
granin-like
protein that is packaged and proteolytically processed within the regulated secretory pathway. VGF and
peptides derived from its processing have been implicated in neuroplasticity associated with learning, memory, depression, and
chronic pain. In sensory neurons, VGF is rapidly increased following
peripheral nerve injury and
inflammation. Several bioactive
peptides generated from the C-terminus of VGF have pronociceptive spinal effects. The goal of the present study was to examine the spinal effects of the
peptide TLQP-21 and determine whether it participates in spinal mechanisms of persistent
pain. Application of exogenous TLQP-21 induced dose-dependent
thermal hyperalgesia in the warm-water immersion tail-withdrawal test. This
hyperalgesia was inhibited by a
p38 mitogen-activated protein kinase inhibitor, as well as inhibitors of
cyclooxygenase and
lipoxygenase. We used immunoneutralization of TLQP-21 to determine the function of the endogenous
peptide in mechanisms underlying persistent
pain. In mice injected intradermally with complete
Freund adjuvant, intrathecal treatment with anti-TLQP-21 immediately prior to or 5hours after induction of
inflammation dose-dependently inhibited tactile
hypersensitivity and
thermal hyperalgesia. Intrathecal anti-TL21 administration also attenuated the development and maintenance of tactile
hypersensitivity in the spared nerve injury model of
neuropathic pain. These results provide evidence that endogenous
TLQP-21 peptide contributes to the mechanisms of spinal neuroplasticity after
inflammation and nerve injury.